| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | apt |
| Uniprot No | P31166 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-243aa |
| 氨基酸序列 | MQTIIISPLVSHRLCLARAVPCNRLLNNHHRAPPSIRLSNHRSTTSLRLFSSAAASRDSEMATEDVQDPRIAKIASSIRVIPDFPKPGIMFQDITTLLLDTEAFKDTIALFVDRYKDKGISVVAGVEARGFIFGPPIALAIGAKFVPMRKPKKLPGKVISEEYSLEYGTDTIEMHVGAVEPGERAIIIDDLIATGGTLAAAIRLLERVGVKIVECACVIELPELKGKEKLGETSLFVLVKSAA |
| 预测分子量 | 26,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APT重组蛋白的3条参考文献示例(内容为虚构，仅作格式参考)：
1. **《重组APT酶在大肠杆菌中的高效表达及纯化》**
作者：李明等
摘要：研究通过优化密码子及诱导条件，实现大肠杆菌中重组APT酶的高效可溶性表达，并建立镍柱亲和层析纯化流程，为APT酶工业化生产提供参考。
2. **《基于适配体的重组蛋白检测传感器开发》**
作者：Chen, L., & Wang, H.
摘要：构建基于核酸适配体的电化学传感器，特异性识别血清中重组靶蛋白，灵敏度达0.1 nM，应用于疾病标志物的快速检测。
3. **《APT-重组融合蛋白靶向递送抗肿瘤药物的研究》**
作者：Smith, J., et al.
摘要：设计APT结构域与治疗性蛋白的融合表达体系，证明其可精准结合肿瘤细胞表面受体，增强药物靶向性并降低小鼠模型中的系统性毒性。
Aptamer-linked recombinant proteins, often abbreviated as apt-recombinant proteins, represent a novel class of bioengineered molecules that combine the target-binding specificity of aptamers with the functional versatility of recombinant proteins. Aptamers are single-stranded DNA or RNA oligonucleotides selected through SELEX (Systematic Evolution of Ligands by Exponential Enrichment) to bind specific molecular targets with high affinity. Recombinant proteins, produced via genetic engineering in host systems like *E. coli* or mammalian cells, are widely used in therapeutics, diagnostics, and research due to their programmable design and scalability.
The fusion of aptamers with recombinant proteins emerged to address limitations of traditional antibody-based systems, such as immunogenicity, production complexity, and stability. Apt-recombinant proteins leverage aptamers' small size, low cost, and rapid customization while incorporating protein domains for enhanced functionality—e.g., enzymatic activity, signaling modulation, or targeted drug delivery. For example, aptamers can guide recombinant enzymes to diseased cells, improving therapeutic precision in cancer or inflammatory disorders.
This technology gained momentum in the 2010s with advancements in synthetic biology and nucleic acid-protein conjugation techniques. Applications span diagnostics (biosensors, imaging probes), therapeutics (targeted therapies, immunomodulation), and biomanufacturing (affinity purification tools). Challenges include optimizing linker designs for stability, minimizing steric interference between domains, and ensuring in vivo efficacy. Despite these hurdles, apt-recombinant proteins are increasingly explored as modular, multifunctional tools in precision medicine and biotechnology, offering a flexible alternative to conventional biologics.
×
